InterCure Ltd.

Tel Aviv Stock Exchange INCR.TA

InterCure Ltd. Receivables for the year ending December 31, 2023: USD 16.83 M

InterCure Ltd. Receivables is USD 16.83 M for the year ending December 31, 2023, a 45.34% change year over year. Receivables are the amounts owed to the company by customers for goods sold or services rendered.

InterCure Ltd. Receivables for the year ending December 31, 2022 was USD 11.58 M, a -4.11% change year over year.
InterCure Ltd. Receivables for the year ending December 31, 2021 was USD 12.08 M, a 211.53% change year over year.
InterCure Ltd. Receivables for the year ending December 31, 2020 was USD 3.88 M, a 745.24% change year over year.
InterCure Ltd. Receivables for the year ending December 31, 2019 was USD 458.71 K.

Key data

Date	Receivables	Inventory	Goodwill	Total Assets

Tel Aviv Stock Exchange: INCR.TA

InterCure Ltd.

CEO	Mr. Alexander Rabinovich
IPO Date	Sept. 9, 2007
Location	Israel
Headquarters	85 Medinat ha-Yehudim Street
Employees	270
Sector	Consumers Staples
Industries Tobacco Alcoholic Beverages Biotechnology Bread & Bakery Cosmetics Personal Care Pharmaceuticals

Description

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally. It offers dried cannabis inflorescences and cannabis extract mixed with oil. The company also invests in biomed sector. InterCure Ltd. was incorporated in 1994 and is headquartered in Herzliya, Israel.

Key trends

Past 5 years